Fidelity Investments’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-18,126,264
| Closed | -$225M | – | 2774 |
|
|
2016
Q4 | $225M | Buy |
18,126,264
+2,922,161
| +19% | +$35.2M | 0.03% | 619 |
|
|
2016
Q3 | $208M | Buy |
15,204,103
+9,074,047
| +148% | +$91.1M | 0.03% | 652 |
|
|
2016
Q2 | $45.3M | Buy |
6,130,056
+2,589,810
| +73% | +$19.4M | 0.01% | 1319 |
|
|
2016
Q1 | $22.6M | Sell |
3,540,246
-2,819,000
| -44% | -$15.8M | ﹤0.01% | 1607 |
|
|
2015
Q4 | $39.7M | Sell |
6,359,246
-1,213,600
| -16% | -$7.96M | 0.01% | 1353 |
|
|
2015
Q3 | $44.2M | Sell |
7,572,846
-794,600
| -9% | -$6.12M | 0.01% | 1301 |
|
|
2015
Q2 | $69.2M | Sell |
8,367,446
-820,791
| -9% | -$7.26M | 0.01% | 1198 |
|
|
2015
Q1 | $75.7M | Sell |
9,188,237
-30,700
| -0.3% | -$227K | 0.01% | 1153 |
|
|
2014
Q4 | $63.3M | Sell |
9,218,937
-402,000
| -4% | -$2.51M | 0.01% | 1221 |
|
|
2014
Q3 | $52M | Sell |
9,620,937
-3,759,109
| -28% | -$22M | 0.01% | 1289 |
|
|
2014
Q2 | $85.2M | Hold |
13,380,046
| – | – | 0.01% | 1093 |
|
|
2014
Q1 | $108M | Sell |
13,380,046
-3,688,700
| -22% | -$28.7M | 0.02% | 942 |
|
|
2013
Q4 | $116M | Sell |
17,068,746
-2,522,084
| -13% | -$13.6M | 0.02% | 885 |
|
|
2013
Q3 | $360M | Buy |
19,590,830
+2,301,514
| +13% | +$44.7M | 0.06% | 393 |
|
|
2013
Q2 | $302M | Buy |
+17,289,316
| New | +$306M | 0.05% | 417 |
|
Other funds holding ARIA
Fidelity Investments's ARIA Position: Q1 2017 in Review
Fidelity Investments sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 18,126,264 shares — an estimated $225M sold.
Fidelity Investments first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $360M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Fidelity Investments reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Fidelity Investments sold 18,126,264 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $225M.
- Fidelity Investments first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Fidelity Investments's Ariad Pharmaceuticals Inc position peaked at $360M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Fidelity Investments's 13F filing for Q1 2017, filed 11 May 2017.